bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Authors: Kizilbash Sani H. , Gupta Shiv K. , Parrish Karen E. , Laramy Janice K. , Kim Minjee , Gampa Gautham , Carlson Brett L. , Bakken Katrina K. , Mladek Ann C. , Schroeder Mark A. , Decker Paul A. , Elmquist William F. , Sarkaria Jann N.
Published: April 2023

In vivo efficacy of tesevatinib 70 mg/kg in PDX GBM models
Figure S1 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Associations between tested SNPs and clinical outcomes
Supplementary video S1 from Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity in vivo
Authors: Iuliano Luca , Drioli Sara , Pignochino Ymera , Cafiero Claudia Maria , Minisini Martina , D'Este Francesca , Picco Raffaella , Dalla Emiliano , Giordano Giorgia , Grignani Giovanni , Di Giorgio Eros , Benedetti Fabio , Felluga Fulvia , Brancolini Claudio
Published: April 2023

Mitochondrial dynamics in untreated SK-UT-1 cells
Table S4 from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer
Authors: Tsujii Shigehiro , Serada Satoshi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Nomura Taisei , Murakami Ichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Table S4
Supplementary Tables and Figures from PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation
Authors: Scarpa Mario , Singh Prerna , Bailey Christopher M. , Lee Jonelle K. , Kapoor Shivani , Lapidus Rena G. , Niyongere Sandrine , Sangodkar Jaya , Wang Yin , Perrotti Danilo , Narla Goutham , Baer Maria R.
Published: April 2023

Supplementary Table S1. AML patients. Supplementary Table S2. RT-qPCR primers. Supplementary Table S3. IC50 concentrations (nM) of FLT3 inhibitors, PP2A activators and GSK-3beta inhibitors. Supplementary Figure S1. Concurrent PP2A-activating drug treatment increases cytotoxicity of FLT3 inhibitors in Ba/F3-ITD cells with FLT3-ITD and in an MV4-11 orthotopic mouse model. Supplementary Figure S2. Chou-Talalay analysis of FLT3-WT cell lines. Supplementary Figure S3. Images of all mice in the in vivo experiment. Supplementary Figure S4. Concurrent treatment with PP2A-activating drug and FLT3 inhibitor does not induce apoptosis in wild-type FLT3 AML, AML complete remission (CR) or AML complete remission with incomplete platelet recovery (CRp) marrows. Supplementary Figure S5. Concurrent treatment with PP2A-activating drug and FLT3 inhibitor downregulates c-Myc and Pim-1 protein expression in cells with FLT3-ITD. Supplementary Figure S6. p-c-Myc (T58) and p-c-Myc (S62) expression in Ba/F3-ITD and MV4-11 cells treated with gilteritinib and/or FTY720. Supplementary Figure S7. Concurrent treatment with PP2A-activating drug and FLT3 inhibitor produces variable changes in c-Myc and Pim-1 mRNA expression in cells with FLT3-ITD. Supplementary Figure S8. c-Myc and Pim-1 expression in FLT3-WT AML blasts treated with gilteritinib and/or FTY720. Supplementary Figure S9. Proteasome inhibition inhibits downregulation of c-Myc and Pim-1 expression by concurrent PP2A-activating drug and FLT3 inhibitor treatment. Supplementary Figure S10. Concurrent PP2A-activating drug and FLT3 inhibitor treatment increases c-Myc and Pim-1 protein turnover in cells with FLT3-ITD. Supplementary Figure S11. Concurrent PP2A activator and FLT3 inhibitor treatment downregulates p-ERK later than p-AKT in cells with FLT3-ITD. Supplementary Figure S12. The GSK-3beta inhibitor TWS119 prevents c-Myc and Pim-1 downregulation and apoptosis induction by PP2A-activating drug and FLT3 inhibitor combination in Ba/F3-ITD cells.
Supplementary Data from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Supplementary Figures, Tables, Materials and Methods
Figure S7 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S7. The effect of the enzalutamide-mediated increase of DNMT3B expression can be attenuated by targeting DNA methylation or DNMT3B in prostate cancer cells.
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
Authors: Georgiev Peter , Muise Eric S. , Linn Douglas E. , Hinton Marlene C. , Wang Yun , Cai Mingmei , Cadzow Louise , Wilson Douglas C. , Sukumar Selvakumar , Caniga Michael , Chen Lan , Xiao Hui , Yearley Jennifer H. , Sriram Venkataraman , Nebozhyn Michael , Sathe Manjiri , Blumenschein Wendy M. , Kerr Kimberly S. , Hirsch Heather A. , Javaid Sarah , Olow Aleksandra K. , Moy Lily Y. , Chiang Derek Y. , Loboda Andrey , Cristescu Razvan , Sadekova Svetlana , Long Brian J. , McClanahan Terrill K. , Pinheiro Elaine M.
Published: April 2023

Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
Figure S6 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S6. RNA-seq analysis reveals new genes responsible for enzalutamide resistance
Supplementary figures and legends from AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer
Authors: Zhang Yuqing , Arner Emily N. , Rizvi Ali , Toombs Jason E. , Huang Huocong , Warner Steven L. , Foulks Jason M. , Brekken Rolf A.
Published: April 2023

Supplementary figures show the efficacy of TP-0903 and its effects on tumor infiltrating immune cells and EMT markers expression.
Figure S4 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S4. Decitabine and enzalutamide combination induces an increase of apoptosis and a decrease of cell proliferation in 22Rv1 xenograft tumors.
Supplementary Figure from ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
Authors: Wiedemeyer Wolf R. , Gavrilyuk Julia , Schammel Alexander , Zhao Xi , Sarvaiya Hetal , Pysz Marybeth , Gu Christine , You Monica , Isse Kumiko , Sullivan Theodore , French Dorothy , Lee Christina , Dang Angeline T. , Zhang Zhaomei , Aujay Monette , Bankovich Alexander J. , Vitorino Philip
Published: April 2023

Supplementary Figure from ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs
Authors: Gilardi Mara , Saddawi-Konefka Robert , Wu Victoria H. , Lopez-Ramirez Miguel Angel , Wang Zhiyong , Soto Fernando , Ramms Dana J. , Proietto Marco , Mikulski Zbigniew , Miki Haruka , Sharabi Andrew , Kupor Daniel , Rueda Ricardo , Hollern Daniel P. , Wang Joseph , Gutkind J. Silvio
Published: April 2023

Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs
Supplementary Fig S1 from IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer
Authors: Markov Spas Dimitrov , Caffrey Thomas C. , O'Connell Kelly A. , Grunkemeyer James A. , Shin Simon , Hanson Ryan , Patil Prathamesh P. , Shukla Surendra K. , Gonzalez Daisy , Crawford Ayrianne J. , Vance Krysten E. , Huang Ying , Eberle Kirsten C. , Radhakrishnan Prakash , Grandgenett Paul M. , Singh Pankaj K. , Madiyalakan Ragupathy , Daniels-Wells Tracy R. , Penichet Manuel L. , Nicodemus Christopher F. , Poole Jill A. , Jaffee Elizabeth M. , Hollingsworth Michael A. , Mehla Kamiya
Published: April 2023

Amino acid sequence of anti-MUC1.IgE antibody
Supplementary Figure from Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors
Authors: Martin Alexandra L. , Anadon Carmen M. , Biswas Subir , Mine Jessica A. , Handley Katelyn F. , Payne Kyle K. , Mandal Gunjan , Chaurio Ricardo A. , Powers John J. , Sprenger Kimberly B. , Rigolizzo Kristen E. , Innamarato Patrick , Harro Carly M. , Mehta Sumit , Perez Bradford A. , Wenham Robert M. , Conejo-Garcia Jose R.
Published: April 2023

Supplementary Figure from Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors
Supplementary Data from Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors
Authors: Martin Alexandra L. , Anadon Carmen M. , Biswas Subir , Mine Jessica A. , Handley Katelyn F. , Payne Kyle K. , Mandal Gunjan , Chaurio Ricardo A. , Powers John J. , Sprenger Kimberly B. , Rigolizzo Kristen E. , Innamarato Patrick , Harro Carly M. , Mehta Sumit , Perez Bradford A. , Wenham Robert M. , Conejo-Garcia Jose R.
Published: April 2023

Supplementary Data from Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors
Supplementary Data from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Authors: Spiliopoulou Pavlina , Spear Sarah , Mirza Hasan , Garner Ian , McGarry Lynn , Grundland-Freile Fabio , Cheng Zhao , Ennis Darren P. , Iyer Nayana , McNamara Sophie , Natoli Marina , Mason Susan , Blyth Karen , Adams Peter D. , Roxburgh Patricia , Fuchter Matthew J. , Brown Bob , McNeish Iain A.
Published: April 2023

Supplementary Data from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Supplementary Table from Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling
Authors: Pan Xinxing , Geng Zhe , Li Jingyun , Li Xingxing , Zhang Mi , Wang Xusu , Cong Yu , Huang Ke , Xu Juan , Jia Xuemei
Published: April 2023

Supplementary Table from Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling
Supplementary Materials and Methods from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
Authors: Vernooij Lindy , Bate-Eya Laurel T. , Alles Lindy K. , Lee Jasmine Y. , Koopmans Bianca , Jonus Hunter C. , Schubert Nil A. , Schild Linda , Lelieveld Daphne , Egan David A. , Kerstjens Mark , Stam Ronald W. , Koster Jan , Goldsmith Kelly C. , Molenaar Jan J. , Dolman M. Emmy M.
Published: April 2023

Supplementary information on the used materials and methods.
Supplementary Figure from Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling
Authors: Pan Xinxing , Geng Zhe , Li Jingyun , Li Xingxing , Zhang Mi , Wang Xusu , Cong Yu , Huang Ke , Xu Juan , Jia Xuemei
Published: April 2023

Supplementary Figure from Peptide PDHPS1 Inhibits Ovarian Cancer Growth through Disrupting YAP Signaling
Supplemental Figure 1 from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Authors: Cerniglia Michael , Xiu Joanne , Grothey Axel , Pishvaian Michael J. , Baca Yasmine , Hwang Jimmy J. , Marshall John L. , VanderWalde Ari M. , Shields Anthony F. , Lenz Heinz-Josef , Korn W. Michael , Salem Mohamed , Philip Philip A. , Goldberg Richard M. , Zeng Jia , Kim Sunnie S.
Published: April 2023

Supplemental Figure 1
Supplementary Figure from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Authors: Wang Yifei , Tian Xiangjun , Zhang Wendong , Zhang Zhongting , Lazcano Rossana , Hingorani Pooja , Roth Michael E. , Gill Jonathan D. , Harrison Douglas J. , Xu Zhaohui , Jusu Sylvester , Kannan Sankaranarayanan , Wang Jing , Lazar Alexander J. , Earley Eric J. , Erickson Stephen W. , Gelb Tara , Huxley Philip , Lahdenranta Johanna , Mudd Gemma , Kurmasheva Raushan T. , Houghton Peter J. , Smith Malcolm A. , Kolb Edward A. , Gorlick Richard
Published: April 2023

Supplementary Figure from Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Supplementary Data from VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
Authors: Ekstrom Thomas L. , Pathoulas Nicholas M. , Huehls Amelia M. , Kanakkanthara Arun , Karnitz Larry M.
Published: April 2023

Supplementary Figures S1-S7, figure legends, and Tables S1 and S2.
Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Authors: Dong Yiyu , Gong Yongxing , Kuo Fengshen , Makarov Vladimir , Reznik Ed , Nanjangud Gouri J. , Aras Omer , Zhao Huiyong , Qu Rui , Fagin James A. , Sherman Eric J. , Xu Bin , Ghossein Ronald , Chan Timothy A. , Ganly Ian
Published: April 2023

Quantitative RT-PCR primer sequences
Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Authors: Dong Yiyu , Gong Yongxing , Kuo Fengshen , Makarov Vladimir , Reznik Ed , Nanjangud Gouri J. , Aras Omer , Zhao Huiyong , Qu Rui , Fagin James A. , Sherman Eric J. , Xu Bin , Ghossein Ronald , Chan Timothy A. , Ganly Ian
Published: April 2023

A, Combination treatment of XTC.UC1 with rapamycin and the pan-AKT inhibitor MK2206 and MEK inhibitor PD325902. B, Cell proliferation assay of XTC.UC1 cells treated with rapamycin or AZD8055 alone and in combination with MK2206 or PD325902. C, Immunoblot analysis of mTOR signaling at 5 hours after treatment with rapamycin or AZD 8055 alone and in combination with MK2206 or PD325902. Rapamycin combined with MK2206 did not further reduce cell proliferation, despite inhibition of p-AKT(S473). Rapamycin combined with PD325901 did not result in further reduction of cell proliferation.
Figure S3 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Authors: Dong Yiyu , Gong Yongxing , Kuo Fengshen , Makarov Vladimir , Reznik Ed , Nanjangud Gouri J. , Aras Omer , Zhao Huiyong , Qu Rui , Fagin James A. , Sherman Eric J. , Xu Bin , Ghossein Ronald , Chan Timothy A. , Ganly Ian
Published: April 2023

mTOR inhibitor treatment suppresses XTC.UC1 cell proliferation in vitro. Comparison of dose response of three mTOR inhibitors rapamycin, AZD8055 and AZD2014 in XTC.UC1 cells with 16-day-treatment.
Figure S2 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Authors: Dong Yiyu , Gong Yongxing , Kuo Fengshen , Makarov Vladimir , Reznik Ed , Nanjangud Gouri J. , Aras Omer , Zhao Huiyong , Qu Rui , Fagin James A. , Sherman Eric J. , Xu Bin , Ghossein Ronald , Chan Timothy A. , Ganly Ian
Published: April 2023

Pan-AKT inhibitor treatment of XTC.UC1 cells does not result in large decreases in proliferation. A, Comparison of MK2206 treatment in NTHY-ori (top) and XTC.UC1 (bottom) cells. B, Immunoblot analysis of mTOR signaling in NTHY-ori and XTC.UC1 cells treated with MK2206 for 0, 1, 2, and 3 days.
Supplementary Data from SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy
Authors: Zhang Yajing , Yu Xiaohong , Liu Qiuping , Gong Haiping , Chen An-an , Zheng Hongjun , Zhong Shi , Li Yi
Published: April 2023

Fig. S1 shows the SAGE1 expression in NSCLC samples. Fig. S2 shows the PCR products visualized by gel electrophoresis. Fig. S3 shows the proportion of SAGE1597-606-HLA-A24 specific population before and after first stimulation in CD8+ T cells. Fig. S4 shows the FACS staining of non-SAGE1 specific T cells. Fig. S5 shows the KD and Tm values of SAGE1597-606-specific TCRs refolded in vitro. Fig. S6 shows the activation and cytotoxic activity of non-transduced or an irrelevant TCR or GFP-transduced T cells against tumor cells. Fig. S7 shows the number of apoptotic tumor cells in co-cultured with GFP- transduced T cells. Fig. S8 shows the confluence of remaining tumor cells at the endpoint of the IncuCyte assay. Fig. S9 shows the SAGE1 expression in 95D xenograft. Fig. S10 shows the HLA-A11 peptide-specific CTLs induced from two donors. Fig. S11 shows the increased activation and cytotoxic activity of VF3 mutants transduced T cells. Table S1 shows the SAGE1 expression in tumor cells measured by Nanostring nCounter analysis. Table S2 shows the information of three SAGE1597-606-specific TCRs. Table S3 shows the binding of VF TCRs to a panel of irrelevant pHLAs.
Figure S4 from Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Authors: Wang Yuhua , Pandey Ram Naresh , Roychoudhury Kaushik , Milewski David , Kalin Tanya V. , Szabo Sara , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Figure S4 documents the effect of Eya3 loss and BZ treatment on DNA damage and repair in tumor cells and how tumor cell conditional medium affects endothelial cell proliferation and migration.
Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Authors: Grinkevitch Vera , Wappett Mark , Crawford Nyree , Price Stacey , Lees Andrea , McCann Christopher , McAllister Katherine , Prehn Jochen , Young Jamie , Bateson Jess , Gallagher Lewis , Michaut Magali , Iyer Vivek , Chatzipli Aikaterini , Barthorpe Syd , Ciznadija Daniel , Sloma Ido , Wesa Amy , Tice David A. , Wessels Lodewyk , Garnett Mathew , Longley Daniel B. , McDermott Ultan , McDade Simon S.
Published: April 2023

Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Supplementary Figure from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype
Authors: Preston Samuel E.J. , Emond Audrey , Pettersson Filippa , Dupéré-Richer Daphné , Abraham Madelyn Jean , Riva Alberto , Kinal Mena , Rys Ryan N. , Johnson Nathalie A. , Mann Koren K. , del Rincón Sonia V. , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

Supplementary Figure from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype
Supplementary Data from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype
Authors: Preston Samuel E.J. , Emond Audrey , Pettersson Filippa , Dupéré-Richer Daphné , Abraham Madelyn Jean , Riva Alberto , Kinal Mena , Rys Ryan N. , Johnson Nathalie A. , Mann Koren K. , del Rincón Sonia V. , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

Supplementary Data from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype
Supplementary Figure 3 from Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
Authors: Grayson Korie A. , Hope Jacob M. , Wang Wenjun , Reinhart-King Cynthia A. , King Michael R.
Published: April 2023

Supplementary Figure 3
Supplementary Figure 2 from Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
Authors: Grayson Korie A. , Hope Jacob M. , Wang Wenjun , Reinhart-King Cynthia A. , King Michael R.
Published: April 2023

Supplementary Figure 2
Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor
Authors: Chen Huadong , Diolaiti Morgan E. , O'Leary Patrick C. , Rojc Ajda , Krogan Nevan J. , Kim Minkyu , Ashworth Alan
Published: April 2023

Supplementary Table from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor
Supplementary Figure 1 from Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress
Authors: Grayson Korie A. , Hope Jacob M. , Wang Wenjun , Reinhart-King Cynthia A. , King Michael R.
Published: April 2023

Supplementary Figure 1
Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor
Authors: Chen Huadong , Diolaiti Morgan E. , O'Leary Patrick C. , Rojc Ajda , Krogan Nevan J. , Kim Minkyu , Ashworth Alan
Published: April 2023

Supplementary Data from A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor
Supplementary Table from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Authors: Buonato Janine M. , Edwards Justin P. , Zaritskaya Liubov , Witter Alexandra R. , Gupta Ankit , LaFleur David W. , Tice David A. , Richman Laura K. , Hilbert David M.
Published: April 2023

Supplementary Table from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Supplementary Figure from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Authors: Buonato Janine M. , Edwards Justin P. , Zaritskaya Liubov , Witter Alexandra R. , Gupta Ankit , LaFleur David W. , Tice David A. , Richman Laura K. , Hilbert David M.
Published: April 2023

Supplementary Figure from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Supplementary Data from Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti–PD-L1 Immunotherapy
Authors: Ludwig Nils , Wieteska Łukasz , Hinck Cynthia S. , Yerneni Saigopalakrishna S. , Azambuja Juliana H. , Bauer Richard J. , Reichert Torsten E. , Hinck Andrew P. , Whiteside Theresa L.
Published: April 2023

Gating strategy
Supplementary Data from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Authors: Buonato Janine M. , Edwards Justin P. , Zaritskaya Liubov , Witter Alexandra R. , Gupta Ankit , LaFleur David W. , Tice David A. , Richman Laura K. , Hilbert David M.
Published: April 2023

Supplementary Data from Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Authors: O'Brien Neil A. , Huang Holly K.T. , McDermott Martina S.J. , Madrid Athena M. , Luo Tong , Ayala Raul , Issakhanian Shawnt , Gong Ke Wei , Lu Ming , Zhang Jun , Slamon Dennis J.
Published: April 2023

Supplementary Table from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Supplementary Figure 4 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Authors: Dalton Krista M. , Krytska Kateryna , Lochmann Timothy L. , Sano Renata , Casey Colleen , D'Aulerio Alessia , Khan Qasim A. , Crowther Giovanna Stein , Coon Colin , Cai Jinyang , Jacob Sheeba , Kurupi Richard , Hu Bin , Dozmorov Mikhail , Greninger Patricia , Souers Andrew J. , Benes Cyril H. , Mossé Yael P. , Faber Anthony C.
Published: April 2023

Supplemental Figure 4. Body Weight of Mice for in vivo treatments. (A) Plot of percent change in body weight from pre-treatment body weight in all in-vivo treatments.
Supplementary Figure 3 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Authors: Dalton Krista M. , Krytska Kateryna , Lochmann Timothy L. , Sano Renata , Casey Colleen , D'Aulerio Alessia , Khan Qasim A. , Crowther Giovanna Stein , Coon Colin , Cai Jinyang , Jacob Sheeba , Kurupi Richard , Hu Bin , Dozmorov Mikhail , Greninger Patricia , Souers Andrew J. , Benes Cyril H. , Mossé Yael P. , Faber Anthony C.
Published: April 2023

Supplemental Figure 3. Chemotherapy and venetoclax combination cell viability assays. Cell viability assays were performed for 72h treatment of cyclophosphamide and topotecan, venetoclax, or combination at indicated concentrations, with bliss synergy scores in (A) MYCN-amplified, and (B) MYCN-wild-type cell lines. (C) Plot of Bliss sum of cell lines in A-B, calculated by the summation of the bliss synergy scores across the doses presented.
Supplementary Figure 2 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Authors: Dalton Krista M. , Krytska Kateryna , Lochmann Timothy L. , Sano Renata , Casey Colleen , D'Aulerio Alessia , Khan Qasim A. , Crowther Giovanna Stein , Coon Colin , Cai Jinyang , Jacob Sheeba , Kurupi Richard , Hu Bin , Dozmorov Mikhail , Greninger Patricia , Souers Andrew J. , Benes Cyril H. , Mossé Yael P. , Faber Anthony C.
Published: April 2023

Supplemental Figure 2. PDX ex vivo model demonstrated cleavage of PARP with corresponding NOXA upregulation (A) Western blot of COG-N-561 ex vivo cell line treated overnight with antibodies as indicated.
Supplementary Figure from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Authors: O'Brien Neil A. , Huang Holly K.T. , McDermott Martina S.J. , Madrid Athena M. , Luo Tong , Ayala Raul , Issakhanian Shawnt , Gong Ke Wei , Lu Ming , Zhang Jun , Slamon Dennis J.
Published: April 2023

Supplementary Figure from Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Table S5 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

Screening results T98G Val-083
Supplementary Table S1 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Ingenuity Pathway Analyses (IPA) and Gene Ontology (GO) analyses
Figure S6 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Clustering of differentially expressed genes (DEGs) in canine InvUC.
Table S1 from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

shRNA library
Figure S5 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Cohens'd effect size for changes in phosphorylated BRAF protein with vemurafenib treatment.
Supplementary Figures from Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Authors: Jiménez-Alcázar Miguel , Curiel-García Álvaro , Nogales Paula , Perales-Patón Javier , Schuhmacher Alberto J. , Galán-Ganga Marcos , Zhu Lucía , Lowe Scott W. , Al-Shahrour Fátima , Squatrito Massimo
Published: April 2023

Combined supplementary Figures
Supplementary Table from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Authors: Hollmén Maija , Maksimow Mikael , Rannikko Jenna H. , Karvonen Matti K. , Vainio Marita , Jalkanen Sirpa , Jalkanen Markku , Mandelin Jami
Published: April 2023

Supplementary Table from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Figure S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Kaplan-Meier survival curves for PFI
Supplementary Data from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Authors: Hollmén Maija , Maksimow Mikael , Rannikko Jenna H. , Karvonen Matti K. , Vainio Marita , Jalkanen Sirpa , Jalkanen Markku , Mandelin Jami
Published: April 2023

Supplementary Data from Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers
Supplementary Table S2 from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Authors: Martin-Broto Javier , Lopez-Alvarez Maria , Moura David S. , Ramos Rafael , Collini Paola , Romagosa Cleofe , Bagué Silvia , Renne Salvatore L. , Barisella Marta , Velasco Valerie , Coindre Jean-Michel , Lopez-Lopez Daniel , Dopazo Joaquin , Gambarotti Marco , Braglia Luca , Merlo Domenico Franco , Palmerini Emanuela , Stacchiotti Silvia , Quagliuolo Vittorio L. , Lopez-Pousa Antonio , Grignani Giovanni , Blay Jean-Yves , Brunello Antonella , Gutierrez Antonio , Valverde Claudia , Hindi Nadia , Dei Tos Angelo Paolo , Picci Piero , Casali Paolo G. , Gronchi Alessandro
Published: April 2023

Supplementary Table S2 - Univariate analysis
Figure S4 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

CAGE analysis of CAFs: List of genes up- and downregulated by CnP
Supplementary Table S1 from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Authors: Martin-Broto Javier , Lopez-Alvarez Maria , Moura David S. , Ramos Rafael , Collini Paola , Romagosa Cleofe , Bagué Silvia , Renne Salvatore L. , Barisella Marta , Velasco Valerie , Coindre Jean-Michel , Lopez-Lopez Daniel , Dopazo Joaquin , Gambarotti Marco , Braglia Luca , Merlo Domenico Franco , Palmerini Emanuela , Stacchiotti Silvia , Quagliuolo Vittorio L. , Lopez-Pousa Antonio , Grignani Giovanni , Blay Jean-Yves , Brunello Antonella , Gutierrez Antonio , Valverde Claudia , Hindi Nadia , Dei Tos Angelo Paolo , Picci Piero , Casali Paolo G. , Gronchi Alessandro
Published: April 2023

Supplementary Table S1. Distribution of MRP-1 expression by subtype
Figure S3 from Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68
Authors: Yamanaka Takahiro , Harimoto Norifumi , Yokobori Takehiko , Muranushi Ryo , Hoshino Kouki , Hagiwara Kei , Gantumur Dolgormaa , Handa Tadashi , Ishii Norihiro , Tsukagoshi Mariko , Igarashi Takamichi , Watanabe Akira , Kubo Norio , Araki Kenichiro , Umezawa Kazuo , Shirabe Ken
Published: April 2023

ELISA of CAF-CM and CnP-treated CAF-CM
Supplementary Data from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Authors: Martin-Broto Javier , Lopez-Alvarez Maria , Moura David S. , Ramos Rafael , Collini Paola , Romagosa Cleofe , Bagué Silvia , Renne Salvatore L. , Barisella Marta , Velasco Valerie , Coindre Jean-Michel , Lopez-Lopez Daniel , Dopazo Joaquin , Gambarotti Marco , Braglia Luca , Merlo Domenico Franco , Palmerini Emanuela , Stacchiotti Silvia , Quagliuolo Vittorio L. , Lopez-Pousa Antonio , Grignani Giovanni , Blay Jean-Yves , Brunello Antonella , Gutierrez Antonio , Valverde Claudia , Hindi Nadia , Dei Tos Angelo Paolo , Picci Piero , Casali Paolo G. , Gronchi Alessandro
Published: April 2023

Supplementary Figures (From S1 to S10)
Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Authors: Ehrenfeld Maximilian , Schrade Anna , Flisikowska Tatiana , Perl Markus , Hirsch Noah-David , Sichler Anna , Geyer Laura , Flisikowski Krzysztof , Wilhelm Dirk , Schober Sebastian Johannes , Johannes Ludger , Schnieke Angelika , Janssen Klaus-Peter
Published: April 2023

Supplementary Figure from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure 7 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 7. SHP2 compared to selumetinib in a xenograft mouse model. (A) Immunoblots of the PC-9 xenograft tumors treated with the indicated agents for 7 days. (B) Body weight changes after combination therapy with osimertinib and SHP099 or osimertnib and selumetinib in PC-9 xenograft mice. Error bars represent the standard deviation. (C) Body weight changes after combination therapy with alectinib and SHP099 or alectinib and selumetinib in H3122 xenograft mice. Error bars represent the standard deviation. (D) Body weight changes after combination therapy with crizotinib and SHP099 or crizotinib and selumetinib in ABC-20 xenograft mice. Error bars represent the standard deviation. Osi, osimertinib; Alec, alectinib; Cri, crizotinib; Selu, selumetinib; SHP, SHP099.
Supplementary Figure 6 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 6. Body weight changes in a xenograft mouse model. Of the mice bearing H3122 tumors, those in the vehicle and SHP099 groups were euthanized on days 14 and 21 respectively, as they had reached the humanitarian endpoint due to tumor growth. Error bars represent the standard deviation.
Supplementary Figure 5 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 5. Combined use of RMC4550 with alectinib, crizotinib or osimertinib Immunoblots of the indicated proteins in H3122 and ABC-19 cells treated with alectinib (Alec, 100 nM), HCC78 and ABC-20 cells treated with crizotinib (Cri, 1 µM) and PC-9 and HCC827 cells treated with osimertinib (Osi, 100 nM). All cell lines were also treated with RMC-4550 (RMC, 5 µM). Comb, combination. (B) Cell viability curves plotted for the cell lines treated with the molecular-targeted drug alone (circles), RMC-4550 alone (triangles) or the molecular-targeted drug and RMC-4550 (5 µM) (squares). All drugs were loaded for 96 h. Error bars represent the standard error.
Supplementary Figure 4 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 4. PTPN11 silencing Two different PTPN11-targeting siRNAs were used. SHP2 expression was determined with immunoblotting.
Supplementary Data from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Authors: Ehrenfeld Maximilian , Schrade Anna , Flisikowska Tatiana , Perl Markus , Hirsch Noah-David , Sichler Anna , Geyer Laura , Flisikowski Krzysztof , Wilhelm Dirk , Schober Sebastian Johannes , Johannes Ludger , Schnieke Angelika , Janssen Klaus-Peter
Published: April 2023

Supplementary Data from Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma
Supplementary Figure 1 from SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non–small Cell Lung Cancer
Authors: Kano Hirohisa , Ichihara Eiki , Watanabe Hiromi , Nishii Kazuya , Ando Chihiro , Nakasuka Takamasa , Ninomiya Kiichiro , Kato Yuka , Kubo Toshio , Rai Kammei , Ohashi Kadoaki , Hotta Katsuyuki , Tabata Masahiro , Maeda Yoshinobu , Kiura Katsuyuki
Published: April 2023

Supplementary Figure 1. phospho-RTK array in PC-9 cells phospho-RTK array in PC-9 cells treated with 100 nM of the EGFR TKI erlotinib for up to 96 h. Multiple RTKs were gradually activated over time.
Supplementary Table from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Authors: Cabaud Olivier , Berger Ludovic , Crompot Emerence , Adélaide José , Finetti Pascal , Garnier Sèverine , Guille Arnaud , Carbuccia Nadine , Farina Anne , Agavnian Emilie , Chaffanet Max , Gonçalves Anthony , Charafe-Jauffret Emmanuelle , Mamessier Emilie , Birnbaum Daniel , Bertucci François , Lopez Marc
Published: April 2023

Supplementary Table from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Supplementary Figure from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Authors: Cabaud Olivier , Berger Ludovic , Crompot Emerence , Adélaide José , Finetti Pascal , Garnier Sèverine , Guille Arnaud , Carbuccia Nadine , Farina Anne , Agavnian Emilie , Chaffanet Max , Gonçalves Anthony , Charafe-Jauffret Emmanuelle , Mamessier Emilie , Birnbaum Daniel , Bertucci François , Lopez Marc
Published: April 2023

Supplementary Figure from Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
Figure S5 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

PDAC cells express PD-L1.
Figure S3 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

Flow cytometry gating strategy
Figure S2 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Authors: Wilson Elizabeth A. , Sultana Nahid , Shah Khyati N. , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Figure 2
Figure S1 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
Authors: Wilson Elizabeth A. , Sultana Nahid , Shah Khyati N. , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Figure 1
Figure S1 from Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment
Authors: Hashimoto Masakazu , Konda John David , Perrino Stephanie , Celia Fernandez Maria , Lowy Andrew M. , Brodt Pnina
Published: April 2023

The IGF-Trap alters the tumor immune microenvironment
Supplementary Data 7 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

Body weights for LNCaP F877L xenograft model in castrated male SHO mice
Supplementary Methods from Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences
Authors: Garcia Cesar A. , Bhargav Adip G. , Brooks Mieu , Suárez-Meade Paola , Mondal Sujan K. , Zarco Natanael , ReFaey Karim , Jentoft Mark , Middlebrooks Erik H. , Snuderl Matija , Carrano Anna , Guerrero-Cazares Hugo , Schiapparelli Paula , Sarabia-Estrada Rachel , Quiñones-Hinojosa Alfredo
Published: April 2023

Supplementary Methods
Supplementary Data 4 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

Plasmid maps sequences
Supplementary Data 3 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

The synthetic androgen R1881 induces maximum proliferation in LNCaP AR/cs and LNCaP F877L cell lines at 0.1nM concentrations
Supplementary Data 2 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

Enzalutamide activates AR signaling in the absence of androgen in HepG2 transiently transfected with AR F877L and AR F877L/T878A constructs but not AR T878A only
Supplementary Data 1 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

JNJ-63576253 and enzalutamide inhibit KLK3 and FKBP5 mRNA expression in LNCaP AR/cs.
Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Authors: Werr Lisa , Plenker Dennis , Dammert Marcel A. , Lorenz Carina , Brägelmann Johannes , Tumbrink Hannah L. , Klein Sebastian , Schmitt Anna , Büttner Reinhard , Persigehl Thorsten , Shokat Kevan M. , Wunderlich F. Thomas , Schram Alison M. , Peifer Martin , Sos Martin L. , Reinhardt H. Christian , Thomas Roman K.
Published: April 2023

Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Supplementary Figure from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Authors: Gopinathan Ganga , Berlato Chiara , Lakhani Anissa , Szabova Ludmila , Pegrum Colin , Pedrosa Ana-Rita , Laforets Florian , Maniati Eleni , Balkwill Frances R.
Published: April 2023

Supplementary Figure from Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
Table S2 from Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Authors: Cairns Junmei , Ingle James N. , Kalari Krishna R. , Goetz Matthew P. , Weinshilboum Richard M. , Gao Huanyao , Li Hu , Bari Mehrab Ghanat , Wang Liewei
Published: April 2023

Table S2 shows ERα binding partners in the presence of anastrozole or E2
Table S1 from Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Authors: Cairns Junmei , Ingle James N. , Kalari Krishna R. , Goetz Matthew P. , Weinshilboum Richard M. , Gao Huanyao , Li Hu , Bari Mehrab Ghanat , Wang Liewei
Published: April 2023

Table S1 shows FASN CHIP primers
Supplementary Data from A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy
Authors: Zhang Di , Hou Zhilin , Aldrich Kelly E. , Lockwood Lizbeth , Odom Aaron L. , Liby Karen T.
Published: April 2023

Suppl Fig. 1 lists the primer sequences for NFE2L2 and downstream gene targets of Nrf2. Suppl Fig. 2 shows that MSU38225 does not alter the overall expression pattern of abundant cellular proteins. Suppl Fig. 3 shows that MSU38225 does not inhibit the proliferation of MCF10A cells at concentrations that inhibit the Nrf2 pathway.